RPS6KA6(RSK4)
Sign in to save this workspaceUniProt Q9UK32 · PDB · AlphaFold · Substrate: Long S6 Kinase substrate peptide · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 95.6% | 4.4% | 78.64 | 0.500 |
| 2 | Brigatinib | 95.0% | 5.0% | 82.96 | 0.513 |
| 3 | Sunitinib | 87.7% | 12.3% | 91.73 | 0.524 |
| 4 | Defactinib | 84.4% | 15.6% | 92.68 | 0.450 |
| 5 | Rabusertib | 84.3% | 15.8% | 98.74 | 0.687 |
| 6 | Netarsudil | 83.1% | 16.9% | 93.22 | 0.676 |
| 7 | Nintedanib | 69.2% | 30.8% | 90.23 | 0.608 |
| 8 | Capivasertib | 66.8% | 33.2% | 96.48 | 0.644 |
| 9 | Ceritinib | 56.4% | 43.6% | 95.44 | 0.618 |
| 10 | Bosutinib | 53.2% | 46.8% | 87.22 | 0.555 |
| 11 | Axitinib | 51.1% | 48.9% | 93.23 | 0.688 |
| 12 | Gilteritinib | 50.3% | 49.7% | 88.97 | 0.506 |
| 13 | Alectinib | 49.4% | 50.6% | 95.49 | 0.651 |
| 14 | Selpercatinib | 47.8% | 52.2% | 96.72 | 0.635 |
| 15 | Palbociclib | 40.2% | 59.8% | 98.75 | 0.673 |
| 16 | Darovasertib | 36.5% | 63.5% | 96.99 | 0.719 |
| 17 | Repotrectinib | 34.3% | 65.7% | 84.21 | 0.608 |
| 18 | Deucravacitinib | 32.3% | 67.7% | 98.99 | 0.718 |
| 19 | Fedratinib | 31.3% | 68.7% | 96.21 | 0.576 |
| 20 | Pralsetinib | 27.8% | 72.2% | 93.43 | 0.643 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.01
- Epithelial log2(TPM+1): 0.99
- Fold change: 0.02
- Status: No significant change
Selectivity landscape vs inhibition on RPS6KA6
Each point is one of the 92 approved drugs; color = inhibition % on RPS6KA6.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…